NewsBenzingaaTyrファーマ社、慢性症状性肺サルコイドーシス患者を対象とした第3相試験のプロトコルに関してFDAと合意を達成。リード治療薬候補Efzofitimodに関する研究関連活動を2026年第4四半期に開始予定 aTyrファーマ社、慢性症状性肺サルコイドーシス患者を対象とした第3相試験のプロトコルに関してFDAと合意を達成。リード治療薬候補Efzofitimodに関する研究関連活動を2026年第4四半期に開始予定 Benzinga 2026.09.24 10:07 (GMT+0) Open on Benzinga Other news Dan Ives Says ‘Clearly Jensen Wants to Come Back as CEO’, Sees Potential Special Shareholder Meeting Telsey Advisory Group Maintains Market Perform on Kohl's, Raises Price Target to $25 Red Cat Q3 Revenue Contracts 42% in Q3, Analysts Cut Price Targets Citigroup Maintains Neutral on Petrobras Brasileiro, Lowers Price Target to $18.5 Nike Executive Says 2028 Will Be ‘A Challenging Year Financially’; Co. Expects Adjusted EPS To Decline Modestly In Fiscal 2028 From Fiscal 2027 Levels Lake Street Maintains Buy on Glass House Brands, Lowers Price Target to $3
Nike Executive Says 2028 Will Be ‘A Challenging Year Financially’; Co. Expects Adjusted EPS To Decline Modestly In Fiscal 2028 From Fiscal 2027 Levels